Psoriatic Arthritis

Etanercept is a viable long-term treatment strategy for patients with psoriatic arthritis, and is both safe and effective when used in daily clinical practice, according to a new prospective long-term study.

An analysis of 35 years of cohort data provides fresh information about the biggest risk factors for cardiovascular disease in patients with psoriatic arthritis.

A meta-study of randomized controlled trials indicates that older TNF-inhibitors such as etanercept or infliximab treat psoriatic arthritis more effectively than newer TNF-inhibitors.

Researchers report that tailored, computer-based training and interventions can increase the effectiveness of health promotion programs for many workplaces.

Secukinumab was more effective than placebo in patients with psoriatic arthritis in a second phase 3 trial, strengthening the case for approval as a treatment for the disease.

Evaluating the cost of biologics for treating PsA: Adalimumab associated with highest costs, followed by Golimumab and Etanercept.

Psoriatic arthritis is associated with an additional increase in cardiovascular disease. One hypothesis shows that rheumatic diseases and atherosclerosis may be related due to an inflammatory mechanism.

Two studies published in leading medical journals show that secukinumab, a human monoclonal antibody used to treat psoriasis, could work in psoriatic arthritis.

A German cohort study in Archives of Dermatological Research found that antipsoriatic drugs for treatment of moderate-to-severe psoriasis are generally safe over the long-term.

Ultrasound and fluorescence optical imaging can detect inflammation in hand joints of rheumatoid arthritis and osteoarthritis patients.

T cell activator associated with psoriatic arthritis but not psoriasis.

Longer intervals between injections of anti-TNF drugs in patients with psoriatic arthritis is "safe, effective, cost-effective, and facilitates patient compliance," according to researchers.

Individuals afflicted with psoriasis and psoriatic arthritis are also at higher risk for new-onset migraines.

Tofacitinib, an RA approved drug, shows promise for PsA.

A study of patients undergoing total hip arthroplasty found that patients with psoriatic arthritis face no greater risk of poor outcomes than patients who get hip replacements because of osteoarthritis.

Study shows that patients with psoriatic arthritis and cutaneous psoriasis could be good candidates for total hip replacement.

Adalimumab gets new indication for hidradenitis suppurativa.

Regulators in the UK have decided not to recommend apremilast as an alternative to DMARD therapy in patients with psoriatic arthritis.

Researchers have found further links between vitamin D deficiency and chronic inflammatory rheumatic diseases such as psoriatic arthritis.

Distinguishing between different types of childhood arthritis is not always easy.

Psoriatic arthritis is a complex, understudied condition in older people who need more effective treatments.

Two chemical messengers are the targets of several new drugs that are in clinical trials or approved for treating psoriasis and other autoimmune diseases

Half of the patients with psoriatic arthritis enrolled in a trial of etanercept continued responding to the medication and complying with treatment guidelines for more than 5 years.

New research suggests that a 10-second self assessment might provide nearly as much information about psoriatic arthritis case progression as complex tests that generally require either require laboratory results or formal joint-by-joint evaluation.

Researchers found that adding kunzea oil to topical psoriasis treatments with liquor carbonis detergens (LCD) and salicylic acid did not improve the irritating skin condition.

A small Italian study found no evidence that use of anti-TNF-alpha agents during pregnancy affects the health or development of children in their first 2 years of life.

Inflammatory rheumatic diseases have long been associated with increased morbidity and mortality. A new study compares the prevalence of comorbidities among psoriatic arthritis, rheumatoid arthritis and psoriasis.

Up to one-third of people with active ankylosing spondylitis (AS) have some degree of bone loss due to systemic inflammation and decreased mobility, but lowering inflammation with tumor necrosis factor blockers may improve bone density.

Patients with plaque psoriasis and psoriatic arthritis have seen their treatment options increase in recent years. Thanks to more research on the topic they could see even more options in the years to come.

Researchers found that not only are patients with psoriasis or psoriatic arthritis at higher risk for uveitis, the association is bidirectional: patients with uveitis are at increased risk for psoriasis and psoriatic arthritis